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Background: Cost-utility models are frequently used to compare treatments intended to prevent or delay the
onset of cardiovascular events. Most published utilities represent post-event health states without incorporating the
disutility of the event or reporting the time between the event and utility assessment. Therefore, this study estimated
health state utilities representing cardiovascular conditions while distinguishing between acute impact including the
cardiovascular event and the chronic post-event impact.
Methods: Health states were drafted and refined based on literature review, clinician interviews, and a pilot study.
Three cardiovascular conditions were described: stroke, acute coronary syndrome (ACS), and heart failure. One-year
acute health states represented the event and its immediate impact, and post-event health states represented chronic
impact. UK general population respondents valued the health states in time trade-off tasks with time horizons of one
year for acute states and ten years for chronic states.
Results: A total of 200 participants completed interviews (55% female; mean age = 46.6 y). Among acute health states,
stroke had the lowest utility (0.33), followed by heart failure (0.60) and ACS (0.67). Utility scores for chronic health states
followed the same pattern: stroke (0.52), heart failure (0.57), and ACS (0.82). For stroke and ACS, acute utilities were
significantly lower than chronic post-event utilities (difference = 0.20 and 0.15, respectively; both p < 0.0001).
Conclusions: Results add to previously published utilities for cardiovascular events by distinguishing between chronic
post-event health states and acute health states that include the event and its immediate impact. Findings suggest that
acute versus chronic impact should be considered when selecting scores for use in cost-utility models. Thus, the current
utilities provide a unique option that may be used to represent the acute and chronic impact of cardiovascular conditions
in economic models comparing treatments that may delay or prevent the onset of cardiovascular events.
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Cardiovascular disease is a worldwide health concern
and the primary cause of non-communicable disease-
related death in the United States and Europe [1-4].
Cardiovascular conditions such as heart disease and
stroke are associated with serious acute symptoms
[5-8], long-term disability [9-11], and substantial costs
for patients and healthcare systems [1,12,13]. Treatments
such as statins have been shown to reduce the risk of* Correspondence: Louis.matza@evidera.com
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unless otherwise stated.cardiovascular events [14-16], and new treatments are in
development [17-19].
As new treatments are introduced, cost-effectiveness
analyses are needed to examine and compare their value
relative to existing treatments. Cost-utility analyses (CUA)
are a type of cost-effectiveness analysis commonly con-
ducted to examine treatments for cardiovascular disease
and risk factors such as hyperlipidemia [20-23]. A CUA
requires health state utility values, which represent the
strength of preferences for various health states and are
used to calculate quality-adjusted life years (QALYs)
[24-26]. A recent systematic review found that a wide
range of published utility values are available to representThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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acute coronary syndrome (ACS), and heart failure [27].
An important limitation of available cardiovascular
utilities is that the time between the cardiovascular event
and the utility assessment is not usually reported. For
example, commonly cited studies have derived utilities
from large surveys in which individuals provided assess-
ments of their own health using a generic preference-
based measure [28,29]. These studies reported utilities
for subgroups of patients who had experienced cardio-
vascular events, such as stroke or myocardial infarction,
at an unspecified time in their medical history. There-
fore, the resulting utility values represent a post-event
health state rather than the event itself, and the utility
assessment may have occurred many years after the car-
diovascular event when patients may have substantially
recovered. Because time between the cardiovascular
event and utility assessment is not known, the utilities
do not necessarily capture the impact of the event or the
substantial quality-of-life impact that occurs during the
first months or even years following the event. Due to
this limitation, utilities from studies that do not report
duration of time between the cardiovascular event and
utility assessment are difficult to interpret and may
underestimate the disutility of cardiovascular events.
Some studies address this problem by documenting
and reporting the time between the cardiovascular event
and utility assessment. For example, studies conducted
in Thailand, the Netherlands, Sweden, and the UK have
reported EQ-5D values for stroke patients at specific
time points after the event including two months [30],
three months [31], six months [30-32], nine months
[31], and/or 12 months [31] post-stroke. Other studies
have evaluated utilities at specific time points in relation
to hospital discharge [32-36]. Studies in the UK, Australia,
and multiple European countries have identified EQ-5D
values for myocardial infarction or angina patients before
hospital discharge [37], at discharge [38], six weeks
[37,39], three months [37], and/or one year [38] after the
event. However, all of these studies may also be underesti-
mating the impact of cardiovascular events because they
do not capture the disutility of the event itself.
Therefore, the purpose of this study was to estimate
utilities of health states representing cardiovascular
conditions while distinguishing between chronic post-
event impact and acute impact including the cardiovascu-
lar event. Researchers have commented that it would be
difficult or perhaps impossible to have patients complete a
generic preference-based measure (e.g., EQ-5D) or an-
other type of utility rating in the acute phases immediately
following a major cardiovascular event, such as a stroke
[30,40-42]. As an alternative method, the current study
used a health state description (often called a vignette-
based) utility assessment approach, which allowed forassessment of chronic post-event health states as well as
acute health states including the event itself. Acute health
states described a year beginning with the cardiovascular
event, followed by description of a typical course of recov-
ery for the remainder of the one-year duration. Chronic
health states described patients experiencing ongoing
effects of cardiovascular events that occurred in the past.
All health states were valued by general population
respondents in time trade-off (TTO) tasks, with a one-
year time horizon for acute health states and a 10-year
time horizon for chronic health states.
Methods
Overview of study design
Health state descriptions were drafted based on litera-
ture review and input from clinicians who treat cardio-
vascular disease. Then, the health states were refined
based on additional clinician interviews and a pilot study
with general population respondents in Edinburgh, UK.
Finally, health states were rated in a TTO valuation
study with general population participants in Edinburgh
and London, UK.
Three cardiovascular conditions were represented in the
health states (stroke, ACS, heart failure). For each of these
three conditions, a one-year health state was drafted to
represent the acute impact, and a post-event health state
was drafted to represent ongoing chronic impact. Every
participant rated all six health states, and to control for
order effects, participants were randomized to begin with
either the chronic or the acute health states.
Health state development
Throughout the health state development process, tele-
phone interviews were conducted with a total of nine clini-
cians (all with MD and/or MBChB degrees) including six
cardiologists, two neurologists (who primarily described pa-
tients’ experiences of stroke), and one chemical pathologist
specializing in diseases related to hyperlipidemia. Five of
the clinicians were from the US, while the other four were
based in the UK. In the initial phase, telephone interviews
were conducted with six clinicians to inform health state
development with questions focusing on patients’ typical
experiences with stroke, ACS, and heart failure including
symptoms; treatment procedures and regimens; and acute
and chronic impact. To characterize the acute health states,
clinicians were asked to describe the typical patient experi-
ence of the event itself; experiences during and after
hospitalization; typical course of recovery; duration of treat-
ment and hospitalization; and impact on functioning during
the first year after the event. For chronic health states, clini-
cians were asked to describe typical ongoing symptoms,
treatment, and impact in years following an event. Al-
though there is substantial variation in patients’ experiences
of cardiovascular events, clinicians were asked to try to
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ing descriptions.
Draft health states were then sent to two of the original
six clinicians and three new clinicians who provided com-
ments regarding the clarity and accuracy of the descrip-
tions. This process of refining the health states was
iterative, and several of the clinicians were interviewed
multiple times as health states were revised during this
second phase of interviews. Clinicians’ descriptions of the
health states were generally consistent with each other.
For some relatively minor points pertaining to treatment
(e.g., frequency of clinic visits, typical duration of hospital
stay), there were occasional discrepancies between US and
UK clinicians. When these discrepancies arose, health
states were drafted to be consistent with treatment pat-
terns reported by UK clinicians because these descriptions
were intended to be valued in the UK.
Literature review was conducted throughout the
health state development process to inform the clin-
ician interview questions and ensure that the health
state descriptions were consistent with published re-
search. Literature searches focused on the symptoms,
impact, and treatment of stroke [8,9,14], ACS [5,7,43],
and heart failure [15,44,45]. The stroke literature re-
vealed the greatest degree of heterogeneity in patient
experience, ranging from mild stroke with complete
recovery to severe stroke with long-term impairment in
speech, cognition, and mobility [8-10]. During the clin-
ician interviews, the clinicians were asked to provide
descriptions of a stroke of moderate severity. Initially,
literature searches were conducted to identify distinct
characteristics of myocardial infarction and unstable
angina. However, clinicians reported that patients’ ex-
periences of these two cardiovascular events and their
treatment were quite similar, and published literature
often groups these events into the single category of
ACS [5-7,46]. Therefore, acute and chronic health
states representing ACS were drafted, instead of separ-
ate health states representing myocardial infarction and
unstable angina.
Pilot study and selection of utility elicitation methods
After conducting the second round of clinician interviews
and making the corresponding health state revisions, the
health states were tested in a pilot study with 20 general
population participants in Edinburgh, Scotland (13 female;
mean age = 41.5 years; age range = 21 to 74) recruited via
newspaper and online advertisements. In order to identify
the most appropriate utility valuation method for these
health states, each participant valued the states using mul-
tiple methods including TTO and standard gamble (SG)
with several time horizons [24-26]. In utility elicitation
procedures, particularly TTO, the duration of time in the
health state being rated (i.e., the time horizon) is animportant component of the task. This time horizon varies
across TTO studies [47]. The most commonly used TTO
time horizon appears to be 10 years, which provides for
comparability with previously published TTO utility stud-
ies including the influential Measurement and Valuation
of Health (MVH) study that elicited utilities for EQ-5D
health states [48,49]. However, other time horizons are
also frequently used, including shorter durations intended
to match the typical clinical course of the health state
[50-52] or longer time horizons corresponding to each re-
spondent’s additional life expectancy [52-57]. In the pilot
study, 1-year and 6-month time horizons were attempted
for the acute health states. For the chronic health states,
two time horizons were also attempted: a 10-year time
horizon and a time horizon based on each respondent’s
self-reported life expectancy. The order of the methods
(TTO vs. SG) and time horizons was varied.
In this pilot study, participants consistently reported
that the health states were clear and easy to understand.
Some participants suggested minor revisions in format-
ting and word choice, and the health states were edited
accordingly. All TTO and SG methods yielded utility
scores in a reasonable range with logical discrimination
among health states. The TTO method was selected for
use in the subsequent main study because it was rela-
tively easy for participants to understand and complete,
and because it is consistent with the methods used in
many recent utility valuation studies, including the
MVH study [48,49].
Based on pilot study results, the 1-year time horizon
was selected for the acute health states because some par-
ticipants seemed resistant to trading time in the 6-month
TTO, which resulted in a ceiling effect. For chronic health
states, the 10-year time horizon was selected to maintain
consistency with the MVH study. Furthermore, although
the additional life expectancy time horizon yielded logical
results, it resulted in implausible clinical situations in
some cases. For example, younger respondents with lon-
ger additional life expectancies could be presented with an
option of living with chronic heart failure for 40 years,
which may be unrealistically long for this cardiovascular
condition.Final health states administered in the time trade-off
interviews
Six health states describing cardiovascular events were
rated in TTO interviews (see Additional file 1 for full
health state text). To avoid the potential bias that could
be introduced by health state labels, none of the de-
scriptions provided the name of the cardiovascular condi-
tion (i.e., health states did not mention the terms stroke,
myocardial infarction, heart attack, ACS, unstable angina,
or heart failure) [58]. Instead, the health states described
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impact of the events.
Three acute health states described a single year in
which a cardiovascular event occurred. The acute stroke
(health state A) and ACS (B) descriptions consisted of
bullet points grouped into four chronologically ordered
sections: the event, the hospital experience, the first
6 months after the event, and 7 to 12 months after the
event. The acute heart failure health state (C) described
a year in which heart failure occurred for a patient who
was at risk of this event due to previous ACS. This
health state description included: a brief explanation of
the event that occurred before the current year (i.e.,
ACS), current health subsequent to the earlier event,
and the event during the current year (i.e., heart failure).
This health state structure was designed to reflect clini-
cians’ descriptions of the most typical patient who expe-
riences acute heart failure.
The three chronic health states described ongoing
health of individuals with cardiovascular disease. These
health states can be characterized as post-event health
states that describe the ongoing impact of a previous
event on subsequent years, rather than the acute impact
of the event itself. All three descriptions briefly mentioned
the prior event, while focusing primarily on current on-
going health, treatment, and impact. Health states D and E
represented long-term effects of stroke and ACS, respect-
ively. Health state F described a patient with chronic heart
failure, following ACS that had occurred in a prior year.
Participants
Participants were required to be at least 18 years old;
able to understand the assessment procedures; able and
willing to give written informed consent; and residing in
the UK. Inclusion criteria did not specify particular clin-
ical characteristics because interviews were intended to
yield utilities that may be used in cost-utility analyses for
submission to health technology assessment agencies,
most of whom prefer that utilities represent general
population values [59-62]. Participants were recruited
via advertisements in three newspapers in Edinburgh,
two newspapers in London, and the website Gumtree.-
com. Potentially interested individuals left voicemail
messages with their contact information.
Utility interview procedures and scoring
Utilities were derived by eliciting values for the health
state descriptions in a TTO utility interview with a one-
year time horizon for acute health states and a 10-year
time horizon for chronic health states. All participants
evaluated two groups of health states: acute (A, B, C)
and chronic (D, E, F). To control for order effects, par-
ticipants were randomly assigned to rate either the acute
or chronic group first, followed by the other group. Priorto beginning TTO procedures, participants completed an
introductory ranking task intended to familiarize them
with the health state content. During the ranking task, the
three health state descriptions (i.e., either acute or chronic)
were presented to participants on individual cards. Partici-
pants were asked to read the cards carefully and place
them in order from most preferable to least preferable. All
participants completed the ranking task and the TTO for
the first group of three health states before proceeding to
the second group of health states.
For TTO ratings of the acute health states (A, B, C),
participants were offered a choice between spending one
year in the health state being rated or shorter amounts
of time in full health (with choices varying in 1-month
increments). For TTO ratings of the chronic health
states (D, E, F), participants were offered a choice be-
tween spending 10 years in the health state being rated
or a shorter duration in full health (with choices varying
in 1-year increments). Each health state considered bet-
ter than dead received a utility value on a scale with the
anchors of dead (0) and full health (1). The assigned
value was calculated based on the choice in which the
respondent is indifferent between y months/years in the
health state being evaluated and x months/years in full
health (followed by dead). The resulting utility estimate
(u) is calculated as u = x / y.
If participants indicated that a health state was worse
than dead, the interviewer altered the task so that re-
spondents were offered a choice between immediate
death (alternative 1) and a 1-year/10-year life span (alter-
native 2) beginning with varying amounts of time in the
health state being rated, followed by full health for the
remainder of the time horizon (one example of alterna-
tive 2 with a 10-year TTO task would be three years in
health state D, followed by 7 years in full health). For
these health states, the current study used a bounded
scoring approach, which is commonly used for negative
utilities [24]. This scoring approach limits the utility
range of health states worse than dead to values between
0 and −1. To compute these bounded negative utility
values, the Dolan method was used [49], as described
by Rowen & Brazier [63]. This method uses the formula
u = −x / t, where x is the duration of time in full health
and t is the total life span of alternative 2 in the TTO
choice. In the current study, t was one year for acute
states and 10 years for chronic states, which were the
periods of time in the health states being rated plus
subsequent months/years in full health.
Data collection and statistical analysis procedures
Interviews were conducted in private conference rooms
in London and Edinburgh in November 2013. All pro-
cedures and materials were approved by an independ-
ent Institutional Review Board (Ethical & Independent
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participant provided written informed consent before
completing any study procedures. Participants com-
pleted a brief demographic and clinical form, followed
by the TTO utility interview described above. Statistical
analyses were completed using SAS version 9.2 (SAS
Institute, Cary, NC).
Continuous variables, including utilities and pairwise
differences between health state utilities, are summarized
in terms of means and standard deviations, and categorical
variables such as gender and racial/ethnic background are
summarized as frequencies and percentages. Demographic
characteristics of the London and Edinburgh subgroups
were compared with chi-square analyses (for categorical
variables) and t-tests (for continuous variables). Descrip-
tive statistics were also used to summarize willingness to
trade time and rates of positive and negative utilities for
each health state. In addition, pairwise comparisons were
performed using t-tests to compare health states withinTable 1 Demographic characteristics
Characteristic Edinburgh
(N = 107)










Marital Status (n, %)
Single 44 (41.1%)
Married/Living with partner3 46 (43.0%)
Other4 17 (15.9%)
Employment Status (n, %)
Full-time work 28 (26.2%)
Part-time work 34 (31.8%)
Unemployed 9 (8.4%)
Other5 36 (33.6%)
Education Level (n, %)
University degree 48 (44.9%)
No University degree 59 (55.1%)
1P-values are based on t-tests for continuous variables and chi-square analyses for c
2Other self-reported background includes Arab (n = 3) and Latino (n = 2).
3Includes married (n = 64) and living with partner (n = 9).
4Includes divorced (n = 20), separated (n = 6), and widowed (n = 3).
5Includes retired (n = 29), student (n = 15), homemaker (n = 6), disabled (n = 6), “ca
(n = 1), volunteer (n = 1), and unspecified (n = 1).each time horizon (e.g., acute stroke vs. acute ACS) and to
compare analogous cardiovascular events across the time
horizons (e.g., acute stroke vs. chronic stroke).
Results
Sample description
A total of 268 potential participants were reached for
screening. Of these, 262 were eligible, 219 were scheduled
for interviews, and 206 attended the interviews. Six of the
206 participants were unable to complete the TTO inter-
view procedures to provide valid TTO data. Thus, a total
of 200 valid utility interviews were completed.
The sample was 55% female (n = 110), with a mean
age of 46.6 years (Table 1). The majority of participants
reported ethnicity as white (78.0%), and more partici-
pants reported being single (49.0%) than married/living
with a partner (36.5%). Most participants reported being
employed (28.0% full-time and 33.5% part-time). Less






44.5 (14.1) 46.6 (14.9) 0.068
38 (40.9%) 90 (45.0%) 0.27
55 (59.1%) 110 (55.0%)
56 (60.2%) 156 (78.0%) <0.0001
8 (8.6%) 9 (4.5%)
12 (12.9%) 14 (7.0%)
15 (16.1%) 16 (8.0%)
2 (2.2%) 5 (2.5%)
54 (58.1%) 98 (49.0%) 0.053
27 (29.0%) 73 (36.5%)
12 (12.9%) 29 (14.5%)
28 (30.1%) 56 (28.0%) 0.74
33 (35.5%) 67 (33.5%)
7 (7.5%) 16 (8.0%)
25 (26.9%) 61 (30.5%)
41 (44.1%) 89 (44.5%) 0.91
52 (55.9%) 111 (55.5%)
ategorical variables.
reer break” (n = 1), caregiver for elderly parent (n = 1), “live on investments”
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the most common responses were depression (n = 29;
14.5%), arthritis (n = 28; 14.0%), diabetes (n = 12; 6.0%),
hypertension (n = 19; 9.5%), asthma (n = 9; 4.5%), cancer
(n = 9; 4.5%), and thyroid conditions (n = 9; 4.5%). Only
four participants reported cardiovascular conditions, two
with stable angina (1.0%) and two who had experienced a
myocardial infarction (1.0%).
There were no significant differences between the
London (n = 93) and Edinburgh (n = 107) samples in age,
gender, marital status, or employment status (Table 1).
The Edinburgh sample had a significantly higher per-
centage of white participants than the London sample
(93.5% vs. 60.2%; p < 0.0001).
Health state rankings and utilities
In the introductory ranking task, the acute health states
were ranked separately from the chronic health states,
and rankings ranged from 1 (most preferable health
state) to 3 (least preferable health state). For both acute
and chronic health states, stroke was consistently ranked
as least preferable. Mean rankings for the acute health
states were 1.22 (health state B; ACS), 1.96 (C; acute
heart failure), and 2.83 (A; stroke). Mean chronic health
state rankings were 1.03 (E; ACS) 2.42 (F; chronic heart
failure), and 2.56 (D; stroke).
Mean health state utility scores followed the same
order as the health state rankings (Figure 1). For the
acute health states, the cardiovascular event with the
lowest utility was stroke (health state A; utility = 0.33),



































Figure 1 Mean TTO1 utility scores (N = 200). 1TTO utility scores are on a sc
TTO = Time trade-off; ACS = Acute coronary syndrome.Utility scores for chronic health states followed the
same pattern with the lowest utility for stroke (D;
0.52) and higher scores for heart failure (F; 0.57) and
ACS (E; 0.82).Health state comparisons
Each of the acute health states was significantly different
from the other two (Table 2). For example, acute stroke
(A) had a significantly lower utility than both acute ACS
(B) and heart failure (C) with substantial differences
between health states (difference scores = 0.34 and 0.28,
respectively; both p < 0.0001). The difference between
utilities for ACS and heart failure was also statistically
significant (p < 0.0001) but of a smaller magnitude (dif-
ference = 0.07).
Among health states representing long-term effects of
cardiovascular conditions, stroke (D) and chronic heart
failure (F) had substantially lower utilities than ACS (E)
(difference scores = 0.30 and 0.25, respectively; p < 0.0001).
Although the difference between stroke (D) and chronic
heart failure (F) was still statistically significant (p = 0.04),
the difference between these two health states was of a
smaller magnitude (0.05).
Each of the acute health states was also compared
directly to its parallel chronic health state. For stroke
(A vs. D) and ACS (B vs. E), acute utilities were sub-
stantially lower than their parallel chronic utilities (dif-
ference = 0.20 and 0.15, respectively; both p < 0.0001).
The difference between utilities for acute and chronic













Chronic Post Event Health States
ale anchored with 0 representing dead and 1 representing full health.
Table 2 T-tests comparing select pairs of health state utilities (N = 200)
Comparison Health state Mean (SD) utilities1 Mean (SD) difference score t-statistic p-value
Acute Health States
A vs. B A. Stroke 0.33 (0.46) −0.34 (0.35) −14.1 <0.0001
B. Acute Coronary Syndrome 0.67 (0.34)
A vs. C A. Stroke 0.33 (0.46) −0.28 (0.35) −11.1 <0.0001
C. Heart Failure 0.60 (0.38)
B vs. C B. Acute Coronary Syndrome 0.67 (0.34) 0.07 (0.23) 4.3 <0.0001
C. Heart Failure 0.60 (0.38)
Chronic Health States
D vs. E D. Stroke 0.52 (0.38) −0.30 (0.34) −12.6 <0.0001
E. Acute Coronary Syndrome 0.82 (0.17)
D vs. F D. Stroke 0.52 (0.38) −0.05 (0.33) −2.0 0.0429
F. Chronic Heart Failure 0.57 (0.32)
E vs. F E. Acute Coronary Syndrome 0.82 (0.17) 0.25 (0.28) 13.0 <0.0001
F. Chronic Heart Failure 0.57 (0.32)
Acute vs. Chronic Health States
A vs. D A. Stroke 0.33 (0.46) −0.20 (0.40) −7.0 <0.0001
D. Stroke 0.52 (0.38)
B vs. E B. Acute Coronary Syndrome 0.67 (0.34) −0.15 (0.33) −6.5 <0.0001
E. Acute Coronary Syndrome 0.82 (0.17)
C vs. F C. Heart Failure 0.60 (0.38) 0.03 (0.31) 1.4 0.1578
F. Chronic Heart Failure 0.57 (0.32)
1TTO utility scores are on a scale anchored with 0 representing dead and 1 representing full health.
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trade time
Additional descriptive analyses were conducted to
characterize patterns of responses. The majority of partici-
pants rated each of the six health states as better than
dead (i.e., utility score > 0): A (84.0%); B (96.0%); C
(94.5%); D (94.0%); E (100.0%); F (97.0%). Three of the
health states (A, D, and F) were rated as equal to dead
(i.e., utility = 0) by one participant. The health state
receiving the most negative utility ratings was health
state A (acute stroke), which was considered worse than
dead by 31 (15.5%) participants. Health state E (chronic
ACS) did not receive any negative utility scores. The
other four health states (B, C, D, F) were rated as negative
by 5.5% or less of the sample.
As expected for relatively severe medical conditions,
most participants were willing to trade time to avoid liv-
ing in the acute health states. A total of 97.0% (n = 194)
were willing to trade time to avoid stroke (health state
A), 84.5% (n = 169) traded time when presented with
heart failure (C), and 74.5% (n = 149) traded to avoid
ACS (B). Although there was less willingness to trade
when presented with the chronic health states, most par-
ticipants were still willing to trade time to avoid any of
the chronic conditions: 87.0% for stroke, 83.0% for
chronic heart failure, and 51.0% for ACS.Discussion
These results add to previously published utilities for
cardiovascular events by differentiating between acute and
chronic effects. Estimates of clinically important differ-
ences in utilities obtained via direct elicitation methods
(e.g., TTO methods) have suggested that differences of
0.05 to 0.10 can be considered important [25,64]. The
differences between chronic and acute phases of stroke
and ACS identified in the current study clearly exceed
these criteria. These findings suggest that it may be im-
portant to consider whether utilities represent the acute
or chronic impact when selecting scores for use in car-
diovascular cost-utility models. In addition, these results
raise questions about previously published utilities that
have been assessed without knowledge of the duration of
time between the cardiovascular event and the utility
assessment. Given that the disutility associated with car-
diovascular events is likely to vary depending on the dur-
ation of time since the event, it is difficult to interpret
utility values without this information.
Of the cardiovascular conditions rated in the current
study, acute stroke was the least preferred health state
with the lowest mean utility and the greatest proportion
of negative utility scores (15.5%). Almost all respondents
(97.0%) were willing to trade time to avoid living in this
health state. Although chronic stroke had a higher utility
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also considered quite aversive by most participants
(utility = 0.52). When completing the TTO task, re-
spondents often said the stroke health states were par-
ticularly undesirable because of the functional impact
likely to be associated with the impairments in cogni-
tion and mobility. The acute health state representing
a year in which ACS occurs also had a relatively low
utility (0.67), while the chronic ACS health state had a
notably higher utility, which is consistent with clini-
cians’ descriptions of the strong recovery often ob-
served in patients experiencing an ACS.
The two heart failure health states also had relatively low
utilities, with little difference between acute and chronic
heart failure. Unlike stroke and ACS, the chronic heart fail-
ure health state was not drafted to represent the long-term
impact of acute heart failure. Instead, the acute and chronic
health states were qualitatively different from each other, as
described by clinicians interviewed for the current study.
The acute health state was drafted to describe a patient
experiencing an episode of acute heart failure following a
previous ACS event (which occurred prior to the year de-
scribed in the health state), while the chronic episode was
drafted to describe chronic heart failure in a patient who
had previously experienced an ACS event.
It is challenging to place the utilities for the three
acute health states (A, B, C) in the context of previously
published utilities for these cardiovascular conditions.
Whereas previous results are primarily based on assess-
ments of patient health at either an unknown or known
time following a cardiovascular event, the current acute
health states represent a year that includes the event.
Utilities of the current chronic health states (D, E, F) are
more comparable with previously published values, al-
though variation in respondent samples, geographical re-
gion, severity of the health state, and utility elicitation
methods also limit comparability with previous research.
Still, it does appear that utilities in this study are in an
expected range based on previously published cardiovas-
cular utilities. For example, a utility of 0.52 representing
chronic effects of a moderate stroke (health state D) is
roughly in the middle of the range of utilities (0.12 to
0.81) for moderate stroke reported in a review of previ-
ous TTO and SG studies [65]. The lower utility score of
0.33 for the year including a stroke (health state A) is
similar to relatively low values reported by two previous
studies assessing utility with the EQ-5D at time points
during the first year after a stroke, ranging from 0.21 to
0.41 [30,32]. In addition, the lower utility for acute
stroke than for chronic stroke (difference = 0.20) is con-
sistent with the findings of a recent review, which noted
that EQ-5D scores tend to improve over time following
a stroke [27]. However, some contrasting results have
also been reported, including those from two studieswith relatively high utility values during the first year
after a stroke [31,34].
When using the current utility scores in a model, re-
searchers would need to be aware of the difference between
the acute and chronic health states to ensure that values
are being applied appropriately. The three chronic health
states (D, E, F) described stable health with a duration of
10 years occurring after an acute event that happened in a
previous time period. In contrast, the acute health states
(A, B, C) describe an acute event, plus subsequent treat-
ment and recovery in the first year after the acute event.
The three acute health states may be conceptualized as
path states lasting for a total time period of one year. Path
states are health states that describe the experience of a
hypothetical patient who proceeds through a sequence of
different health states [66,67]. Conceptually, the path-state
approach is appealing because the states can be designed to
represent the typical course of a patient with a particular
medical condition. It allows respondents to consider the
duration of each state within the sequence when valuing
the overall path. However, the limitation of this approach is
that the resulting utilities represent the path, rather than
the individual events or health state components within the
path. If participants are rating the path as a whole, it is not
possible to determine the impact of each health-related
event within the path. Therefore, when using the utility
scores for health states A, B, and C in a cost-utility model,
these values would be most appropriately used to represent
a one-year cycle in which the cardiovascular event occurs.
Utility assessment based on hypothetical health states
is associated with limitations that should be considered
when interpreting data. Previous researchers have com-
mented that it would be difficult or impossible to capture
the disutility of these events with the EQ-5D or another
method of assessing patients’ current health [30,40-42].
Essentially, it is not considered feasible to ask patients to
rate their own health during the immediate days or even
weeks after a serious cardiovascular event, particularly a
stroke, which may cause temporary or permanent cogni-
tive impairment. Therefore, the health state description-
based approach was used in the current study because it
was feasible to draft and value health state descriptions
that included the acute events. Although this method is
well-suited for identifying the utility impact of specific
medical events, results should be interpreted with appro-
priate caution. The resulting utility scores represent the
specific health states, which are based on clinicians’ de-
scriptions of a typical patient rather than the broad range
of symptom severity and outcomes that would be ob-
served in an actual patient sample. Therefore, the extent
to which these utilities might differ from values reported
by actual patients living in the health states is not known.
Still, the utility valuation methodology was selected to
maximize comparability to published health state utilities.
Matza et al. BMC Health Services Research  (2015) 15:173 Page 9 of 11For example, health states were valued by UK general
population participants in a TTO task, which is similar to
methods used to value the EQ-5D health states in the
MVH study [48,49].
Another possible limitation of the current study is that
the acute health states, particularly the description of
acute stroke, were longer and more detailed than those
used in many similar studies (see health state text in
Additional file 1). Based on clinicians’ input during
health state development, these details were considered
necessary to accurately represent key aspects of a typical
year beginning with an event and continuing with a
gradual partial recovery. However, due to the length, it is
possible that some participants may not have been able
to consider all parts of the health states when complet-
ing evaluations. Some respondents appeared to attend
primarily to aspects of impaired functioning that were
particularly salient to them, while possibly overlooking
other aspects of the health states. If participants fail to
notice and consider aspects of the health states, this
would lead to some degree of error and inconsistency in
the ratings. Although it is possible that this occurred in
some cases, steps were taken to minimize this risk. For
example, participants were only asked to rate three acute
health states, rather than the larger number of health
states often included in other studies, and the three
chronic health states were presented separately to avoid
providing too much information at once. In addition,
the acute health states were formatted in a series of sec-
tions with headers indicating the chronological struc-
ture, which was intended to ensure that the content and
sequence of information would be clear. Finally, inter-
viewers were carefully trained to ask questions to ensure
that respondents understood and attended to all aspects
of the health states, while avoiding leading questions
that could bias valuations.
The sample recruitment strategy should also be ac-
knowledged as a limitation of the current data. Utilities
were based on evaluations of a general population sam-
ple because most health technology assessment agencies
prefer that utilities represent the general public or soci-
etal view [59-62]. However, the sample was recruited in
only two UK locations, and it should not be considered
nationally representative. The extent to which the
current utility scores would differ from values derived in
a nationally representative sample is not known.
Conclusions
Despite limitations, this study and its methodology have
several strengths. The health state-based method allows
for an addition to published post-event utilities because
the acute values are based on health states that include
cardiovascular events. Thus, the current utilities provide a
unique option that may be used to represent the impact ofcardiovascular conditions in models, possibly supplement-
ing utilities derived from actual patients with standardized
preference-based measures. With the current utilities,
cost-utility models comparing treatments that may delay
or prevent the onset of cardiovascular events can distin-
guish between acute and chronic impact of these cardio-
vascular events.
Additional file
Additional file 1: Cardiovascular Health States.
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